• Ponatinix 45 mg (Ponatinib) Quick View
    • Ponatinix 45 mg (Ponatinib) Quick View
    • ,

    • Ponatinix 45 mg (Ponatinib)

    • Ponatinix 45 mg (Ponatinib) is a cutting-edge, targeted therapy used to treat patients with chronic myeloid leukaemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL), particularly those who have become resistant to previous treatments. Ponatinib, the active ingredient in Ponatinix, is a third-generation tyrosine kinase inhibitor (TKI) that is especially effective against the T315I mutation, which makes many forms…
    • Read more